Loading…
Dermata Therapeutics, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in DRMA.
▼ -100.0% over 5Y.
today you would have $0.11▼ -100.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $2.32 | $13.50 | $91.50 | $981.60 | $4,176.00 | |
| P/B | 1.5x | 1.5x | 4.7x | 0.6x | 13.4x | 1.4x |
| EPS | -$8.16 | -$80.32 | -$399.90 | -$2,088.00 | -$5,832.00 | |
| ROE | -122.65% | -121.45% | -787.11% | -122.65% | -159.60% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BMRABiomerica Inc | $2.14 | — | 2.0x | — | -94.32% | $6.61M |
| CLGNCollPlant Biotechnologies Ltd | $0.36 | — | 1.1x | — | -151.99% | $6.77M |
| VNRXVolitionrx Ltd | $0.45 | — | — | — | — | $6.48M |
| ACONAclarion, Inc. | $2.40 |
Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Company description provided by Yahoo Finance.
| -78.19% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 0.3x |
| — |
| -58.97% |
| $6.92M |
| HCWBHCW Biologics Inc. | $3.43 | — | 0.7x | — | -151.36% | $6.3M |
| SNOASonoma Pharmaceuticals, Inc. | $1.31 | — | 0.8x | — | -42.52% | $6.27M |